Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) EPS (Weighted Average and Diluted) (2021 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 92.62% year-over-year to -$0.0, compared with a TTM value of -$0.0 through Nov 2025, up 92.62%, and an annual FY2025 reading of -$0.0, up 82.68% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.0 for Q4 2025 at CNBX Pharmaceuticals, up from -$0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.64 in Q2 2023 and bottomed at -$1.16 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.16, with a median of -$0.0 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 8091.84% in 2022, then skyrocketed 1380.0% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.01 in 2021, then crashed by 3200.0% to -$0.33 in 2022, then soared by 98.12% to -$0.01 in 2023, then soared by 80.88% to -$0.0 in 2024, then soared by 92.62% to -$0.0 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CNBX at -$0.0 in Q4 2025, -$0.0 in Q3 2025, and -$0.0 in Q2 2025.